Repligen Corporation - Common Stock - Nakit Akışı (NASDAQ:RGEN)

Financials

İşletme faaliyetlerinden elde edilen nakit 62.63 M119.02 M172.08 M113.92 M175.39 M117.42 M 130.71 M Yatırım faaliyetlerinden elde edilen nakit -201.38 M-221.17 M-233.24 M-123.28 M-86.38 M-298.47 M -228.35 M Finansman faaliyetlerinden elde edilen nakit 305.92 M961 K-13.34 M248.96 M-82.9 M-15.21 M -15.72 M Serbest nakit akışı 62.63 M119.02 M172.08 M113.92 M175.39 M91.69 M 104.46 M

Repligen Corporation - Common Stock

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations worldwide.

RGEN

Financials

Repligen Corporation - Common Stock

Haberler

InvestingPro’nun Gerçeğe Uygun Değer modeli Repligen’in %45’lik düşüşünü öngördü

Repligen hissedarları yönetim kurulu adaylarını ve yönetici maaşlarını onayladı

RBC, Repligen hissesi için kapsamı yeniden başlattı

Alger Mid Cap 40 ETF Q1 2026 Portfolio Movers

Repligen hissesi 109,44 dolarla 52 haftalık dibe vurdu

Repligen’in 1Ç 2026 sonuçları: Gelir %15 arttı, Çin satışları ikiye katlandı

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

Repligen’de gözler çeyrek dönem kazançlarında

Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Alger Mid Cap Growth Fund Q1 2026 Portfolio Review

Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for